Who are LDAC and/or Mitoxantrone's main competitors?

No direct comparators detected in our index.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/ldac-and-or-mitoxantrone.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

LDAC and/or Mitoxantrone — Competitive Intelligence Brief

LDAC and/or Mitoxantrone (LDAC and/or Mitoxantrone) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Chemotherapy combination (nucleoside analog + topoisomerase II inhibitor). Area: Oncology.

phase 3 Chemotherapy combination (nucleoside analog + topoisomerase II inhibitor) DNA polymerase (cytarabine); Topoisomerase II (mitoxantrone) Oncology Small molecule Live · refreshed every 30 min

Target snapshot

LDAC and/or Mitoxantrone (LDAC and/or Mitoxantrone) — DKMS gemeinnützige GmbH. LDAC (low-dose cytarabine) and mitoxantrone are chemotherapy agents that inhibit DNA synthesis and topoisomerase II, respectively, to kill rapidly dividing leukemic cells.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
LDAC and/or Mitoxantrone TARGET	LDAC and/or Mitoxantrone	DKMS gemeinnützige GmbH	phase 3	Chemotherapy combination (nucleoside analog + topoisomerase II inhibitor)	DNA polymerase (cytarabine); Topoisomerase II (mitoxantrone)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Chemotherapy combination (nucleoside analog + topoisomerase II inhibitor) class)

DKMS gemeinnützige GmbH · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). LDAC and/or Mitoxantrone — Competitive Intelligence Brief. https://druglandscape.com/ci/ldac-and-or-mitoxantrone. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab